{
}
Novartis experienced a significant decline in its share price after UBS downgraded its recommendation from "buy" to "neutral," citing concerns over patent expiries for key products like Entresto and Tasigna. The price target was also reduced from 111 to 104 Swiss francs, contributing to a 0.5% drop in shares, contrasting with a 1.1% gain in the SMI index. UBS maintains that Novartis's product portfolio still holds growth potential, but this is now reflected in consensus forecasts.
Novartis' share price declined by 0.5% after UBS downgraded its recommendation from "buy" to "neutral," reducing the price target from 111 to 104 Swiss francs. The analyst noted that while the company's product portfolio has growth potential, upcoming patent expiries for key drugs like Entresto and Tasigna are expected to slow growth significantly this year.
Novartis experienced a significant decline in its share price after UBS downgraded its recommendation from "buy" to "neutral," reducing the price target from 111 to 104 Swiss francs. The analyst noted that while the company's product portfolio has growth potential, upcoming patent expiries for key drugs like Entresto and Tasigna are expected to slow growth this year. Following this news, Novartis shares fell by 0.5%, contrasting with a 1.1% gain in the SMI index.
Novartis experienced a significant decline in its share price after UBS downgraded its recommendation from 'buy' to 'neutral', reducing the price target from 111 to 104 Swiss francs. The downgrade reflects concerns over upcoming patent expiries for key products, which are expected to slow growth this year. Following this news, Novartis shares fell by 0.5%, contrasting with a 1.1% gain in the SMI index.
UBS has adjusted its ratings on key European pharmaceutical companies, downgrading Novartis to Neutral due to concerns over patent expirations and a limited pipeline, while upgrading Roche to Buy, citing strong growth prospects and a robust pipeline. AstraZeneca also received a Buy upgrade, driven by its sector-leading pipeline potential, with both companies seeing significant increases in their price targets.
UBS has downgraded Novartis to Neutral from Buy, citing concerns over patent expirations and a limited pipeline, with EBIT growth expected to decline significantly in 2025. In contrast, Roche and AstraZeneca received upgrades to Buy, driven by strong pipeline prospects and revenue growth potential, with Roche's price target raised to CHF 338 and AstraZeneca's to £142.
UBS has named Roche as its preferred Swiss pharmaceutical stock, upgrading its rating to "Buy" and raising the target price from CHF 300 to CHF 338. The firm cites Roche's sustainable growth, driven by strong performances from Vabysmo and Ocrevus, and anticipates significant sales increases from ongoing development projects, including Ocrevus HD and Trontinemab. While Roche's earnings per share growth is projected at 8.1% from 2024 to 2029, slightly below the industry average, UBS remains optimistic about the company's long-term potential and cash flow for acquisitions.
UBS has downgraded Novartis shares from "Buy" to "Neutral," reducing the price target from 111 to 104 Swiss francs due to limited momentum in its research pipeline. Meanwhile, UBS shares saw a slight increase of 0.10 percent to CHF 30.22, but have declined by 4.17 percent over the past month, with a market capitalization of 110.6 billion euros. Investors are urged to consider their options in light of the latest analysis.
UBS has downgraded Novartis from "Buy" to "Neutral," significantly lowering its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's challenges, including numerous patent expiries and a lack of promising developments in the research pipeline, predicting underperformance through 2025. Novartis shares fell by 1.35% to CHF 96.48 following the announcement.
UBS has downgraded Novartis from "Buy" to "Neutral," reflecting a shift in its outlook for the pharmaceutical giant. The bank has also reduced its target price for Novartis shares from 111 to 104 Swiss francs, indicating a more cautious stance on the stock's performance.
Novartis AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Novartis share price drops as UBS downgrades stock recommendation to neutral
16:36 13.02.2025
Novartis share price declines after UBS downgrades stock recommendation to neutral
16:36 13.02.2025
Novartis shares decline as UBS downgrades stock recommendation to neutral
16:31 13.02.2025
Novartis shares decline as UBS downgrades stock recommendation to neutral
16:31 13.02.2025
ubs adjusts ratings on european pharma stocks novartis downgraded roche upgraded
13:14 13.02.2025
ubs downgrades novartis while upgrading roche and astrazeneca ratings
British Pound Sterling
Swiss Franc
AstraZeneca PLC
Novartis AG
Hoffmann-La Roche AG
GBR
CHE
Show more
13:01 13.02.2025
ubs upgrades roche to preferred pharmaceutical stock with strong growth potential
United States Dollar
Euro
Swiss Franc
Nestlé S.A.
Sanofi
Hoffmann-La Roche AG
Novartis AG
CHE
Show more
12:00 13.02.2025
ubs downgrades novartis shares amid limited research momentum
11:00 13.02.2025
Novartis shares decline as UBS downgrades rating and price target
10:28 13.02.2025
ubs downgrades novartis share price and lowers target valuation
09:33 13.02.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: